e-learning
resources
Barcelona 2013
Tuesday, 10.09.2013
New insights into epigenetic mechanisms in the lung
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Genes affecting mRNA stability and metalloproteinase inhibitor RECK are down-regulated in patients with COPD
Z. Navratilova, T. Krsjakova, E. Novosadova, J. Zatloukal, V. Kolek, M. Petrek (Olomouc, Czech Republic)
Source:
Annual Congress 2013 –New insights into epigenetic mechanisms in the lung
Session:
New insights into epigenetic mechanisms in the lung
Session type:
Oral Presentation
Number:
3512
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Z. Navratilova, T. Krsjakova, E. Novosadova, J. Zatloukal, V. Kolek, M. Petrek (Olomouc, Czech Republic). Genes affecting mRNA stability and metalloproteinase inhibitor RECK are down-regulated in patients with COPD. Eur Respir J 2013; 42: Suppl. 57, 3512
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Panel discussion on ERS Statement – A core outcome set for clinical trials evaluating the management of COPD exacerbations
ERS statement: a core outcome set for clinical trials evaluating the management of COPD exacerbations
Related content which might interest you:
MMP-3 serum levels and
MMP3
-1171insA promoter polymorphism in patients with COPD
Source: International Congress 2014 – Basic and translational research in asthma and COPD
Year: 2014
Downregulation of the pro-apototic gene, BNIPL, in bronchial biopsies from COPD patients
Source: ERS Lung Science Conference 2017
Year: 2017
Surface-bound TIMP-1 on PMNs promotes pericellular proteolysis: A new culprit in COPD?
Source: International Congress 2015 – Airway remodelling: recent developments
Year: 2015
Sputum cell mRNA transcripts demonstrate alteration of endothelin metabolism in severe asthma and COPD
Source: Annual Congress 2013 –New drugs in respiratory medicine
Year: 2013
Downregulation of IL-27 bronchial epithelial expression by heat-shock protein-60
Source: Annual Congress 2013 –Systemic and airway biomarkers in respiratory diseases
Year: 2013
Increased expression of MMP-2 in COPD
Source: Eur Respir J 2005; 26: Suppl. 49, 361s
Year: 2005
-82 A>G promoter polymorphism in the gene of human macrophage elastase (MMP-12) as a risk factor for COPD and bronchial asthma
Source: International Congress 2014 – Basic and translational research in asthma and COPD
Year: 2014
Alterations in gene expression of RAGE and its sheddases in blood of COPD patients do not relate to decreased plasma (e)sRAGE levels
Source: International Congress 2014 – Mechanisms of COPD and inhalation injury
Year: 2014
Egr-1 regulates muc5ac expression through activator protein-1 (AP-1) in chronic airway inflammation diseases
Source: International Congress 2015 – Translational studies in airway cell biology
Year: 2015
Microarrays reveal coordinated expression of ADAMs family of genes in an
in vitro
model of pulmonary fibrosis
Source: Annual Congress 2005 - Progresses in lung fibrosis
Year: 2005
Lung function decline in COPD in relation to MMP-12 and surfactant protein A
Source: International Congress 2016 – New signalling pathways in COPD
Year: 2016
Sputum levels of miR-145 and miR-338 in COPD, asthma and ACOS subjects
Source: International Congress 2016 – Mechanisms of disease
Year: 2016
Plasma levels of TIPM-2 in patients with COPD
Source: International Congress 2016 – Molecular targets in pulmonary disease
Year: 2016
Azithromycin differentially affects IL-13 induced periostin (POSTN), CLCA1 and SERPINB2 expression in human bronchial epithelial cells
Source: International Congress 2015 – Immunomodulation: basic science and clinical aspects
Year: 2015
Identification of novel pathogenic mechanisms triggered by arginase activation in patients with COPD
Source: International Congress 2016 – Airway response to infection
Year: 2016
MMP2 -1306C>T polymorphism and the enzyme plasma levels in patients with COPD
Source: International Congress 2015 – Translational research in respiratory care: new findings
Year: 2015
Matrix metalloproteinase- 9 (MMP-9) and tissue inhibitor of metalloproteinase-1(TIMP-1) as non-invasive biomarkers of remodelling in asthma
Source: International Congress 2015 – Phenotyping asthma with biomarkers
Year: 2015
Genes of detoxication system, matrix metalloproteinase 9 (MMP9) and set of group factors of blood in the risk of development of COPD
Source: Eur Respir J 2004; 24: Suppl. 48, 63s
Year: 2004
MiR-320c regulates SERPINA1 expression and is associated with pulmonary disease in alpha-1-antitrypsin deficiency
Source: International Congress 2016 – How the understanding og molecular and genomic crosstalk is helping to diagnose lung disease
Year: 2016
SIRT1, a histone deacetylase, regulates matrix metalloproteinase-9 expression
Source: Annual Congress 2005 - Pulmonary hypertension and fibrosis: novel mechanisms
Year: 2005
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept